No takes yet. Share an insight, caveat, or question.
In vitro study demonstrates that receptor binding affinity drives distinct metabolic reprogramming in human CD4+ and CD8+ T-cells, indicating pathways for targeted immunotherapies.
Jones et al. (2017) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: